GET DAILY SIGNALSAzenta (AZTA): What to Watch for in Q4 Fiscal 2026 Results
Key Takeaways
- Azenta is expected to report results for the fourth quarter of fiscal 2026 (the three months ended September 30, 2026) in late November 2026.
- Management has guided fourth-quarter organic revenue to decline in the low single digits year over year, weighed down by a tough comparison against the record fourth quarter of fiscal 2025.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) for the fourth quarter is expected to land between roughly $20 million and $23 million.
- Full-year fiscal 2026 reported revenue guidance was raised to a range of $613 million to $618 million following a stronger-than-expected third quarter.
- The third quarter delivered 9% organic revenue growth, supported by Azenta's recurring biorepository and consumables businesses and improved Multiomics performance.
- For more on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- For automated trading ideas, explore Tickeron's Trending AI Robots.
Why the Upcoming Earnings Matter
Azenta, Inc. (Nasdaq: AZTA) operates in life sciences with two main segments: Sample Management Solutions and Multiomics. The fourth-quarter fiscal 2026 report will wrap up a year that included portfolio simplification through the divestiture of B Medical Systems and an upward revision to full-year guidance after a solid third quarter. This print is notable because it will show whether the 9% organic revenue growth from the third quarter can hold up against the record fourth quarter of fiscal 2025. I’m watching margin trends, free cash flow, and any early hints on fiscal 2027 closely as the company continues its margin expansion efforts.
Guidance and Key Benchmarks
Management’s own outlook sets the main reference point ahead of the report. Fourth-quarter organic revenue is expected to fall in the low single digits year over year due to the challenging comparison with fiscal 2025’s record $159 million quarter. Adjusted EBITDA is projected in the $20 million to $23 million range. For the full year, reported revenue guidance was lifted to $613 million to $618 million, with organic revenue seen as flat to up 1%. Segment expectations point to low-single-digit organic growth in Sample Management Solutions and roughly flat to down 1% in Multiomics. The third-quarter non-GAAP earnings per share of $0.16 offers a useful recent benchmark. Metrics such as adjusted EBITDA margin, segment gross margins, free cash flow, and commentary on automated store and cryogenic demand will be worth noting, especially given ongoing macro-related capital spending caution. I also checked this using Tickeron’s AI Screener to compare the stock against peers in the sector.
Investor Sentiment Heading Into the Print
Sentiment appears cautiously optimistic. The third-quarter results from early August 2026 beat the company’s own outlook, with both segments showing organic growth and prompting an increase in full-year revenue guidance. Still, softness in capital equipment areas like automated stores and cryogenic systems persists, as customers delay purchases. Investors are balancing the structural decline in Sanger sequencing against strength in next-generation sequencing, gene synthesis, and recurring revenue streams. The stock’s response will likely depend on whether the fourth-quarter results and any fiscal 2027 comments confirm that third-quarter demand improvement is sustainable.
Looking Ahead to Fiscal 2027 and Beyond
This report will help shape expectations for fiscal 2027 guidance, so management’s forward commentary stands out as the key item. Focus should be on how organic growth is framed across segments amid uneven North American research funding and still-soft capital equipment demand. Margins and cash flow will draw attention too. Full-year fiscal 2026 adjusted EBITDA guidance remains $59 million to $62 million, including about 30 basis points of dilution from the U.K. Biocentre acquisition. Updates on quality remediation costs in automated stores, expected at $5 million to $6 million for the year, should clarify if those expenses are tapering. On the balance sheet, Azenta finished the third quarter with roughly $529 million in cash and marketable securities and no debt while actively buying back shares under a $250 million authorization. Any signals on continued repurchases or capital allocation priorities will help frame the longer-term outlook. From what I see, these elements together provide a fuller picture of the company’s trajectory.
Using AI Tools for Deeper Analysis
In my view, incorporating data-driven tools has become a practical part of reviewing earnings setups like this one. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. These resources help surface relevant patterns and peer comparisons without replacing traditional fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AZTA in upward trend: price rose above 50-day moving average on October 19, 2026
AZTA moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on AZTA as a result. In 60 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for AZTA just turned positive on November 09, 2026. Looking at past instances where AZTA's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.
Following a +9.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTA advanced for three days, in 214 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 130 of 177 cases where AZTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for AZTA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 26 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AZTA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.136) is normal, around the industry mean (4.964). P/E Ratio (-14.558) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (4.143). Dividend Yield (0.010) settles around the average of (0.005) among similar stocks. P/S Ratio (2.485) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AZTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of automation, vacuum and instrumentation solutions
Industry PharmaceuticalsOther
Advertisement